Ascendis Pharma A/S (ASND) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Hellerup, Denmark. 現CEOは Jan Moller Mikkelsen.
ASND を有する IPO日 2015-01-28, 1,017 名の正社員, に上場 NASDAQ Global Select, 時価総額 $15.34B.
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Hellerup, Denmark, dedicated to developing innovative therapeutics for unmet medical needs. The company's commercial product, SKYTROFA, treats growth hormone deficiency in patients, while its robust pipeline includes TransCon-based therapies targeting pediatric and adult growth hormone deficiency, hypoparathyroidism, achondroplasia, and various oncology indications. Founded in 2006, Ascendis leverages its proprietary TransCon technology platform to extend the duration and improve the efficacy of therapeutic proteins across multiple disease areas.
